American Psychiatric Association (2022) Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5-TR. American Psychiatric Association

Book  Google Scholar 

Anderson T, Petranker R, Christopher A, Rosenbaum D, Weissman C, Dinh-Williams LA, Hui K, Hapke E (2019) Psychedelic microdosing benefits and challenges: An empirical codebook. Harm Reduct J 16:1–10. https://doi.org/10.1186/S12954-019-0308-4/FIGURES/3

Article  Google Scholar 

Automeris LLC. (2024). Web Plot Digitizer. Automeris.Io. https://automeris.io/WebPlotDigitizer.html

Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA (2024) Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: A randomized clinical trial. JAMA Network Open 7:e2449026. https://doi.org/10.1001/JAMANETWORKOPEN.2024.49026

Article  PubMed  PubMed Central  Google Scholar 

Bech P (2010) Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 79:331–338. https://doi.org/10.1159/000320118

Article  CAS  PubMed  Google Scholar 

Beck AT, Steer RA, Brown GK (1996) Beck Depression Inventory II (BDI-II). In: Manual for the Beck Depression Inventory–II. Psychological Corporation

Beck AT, Steer RA (1993) Beck depression inventory amended. In manual for the beck depression inventory, The Psychological Corporation Inc

Google Scholar 

Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454–465. https://doi.org/10.1001/JAMA.289.4.454

Article  PubMed  Google Scholar 

Borenstein M, Hedges L, Higgins J, Rothstein H (2013) Comprehensive Meta-Analysis. Englewood, NJ: Bisostat

Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA (2022) Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol 36:1100–1117. https://doi.org/10.1177/02698811221116926/ASSET/IMAGES/LARGE/10.1177_02698811221116926-FIG1.JPEG

Article  PubMed  PubMed Central  Google Scholar 

Butler AC, Chapman JE, Forman EM, Beck AT (2006) The empirical status of cognitive- behavioral therapy: A review of meta-analyses. Clin Psychol Rev 26:17–31. https://doi.org/10.1016/J.CPR.2005.07.003

Article  PubMed  Google Scholar 

Cai N, Choi KW, Fried EI (2020) Reviewing the genetics of heterogeneity in depression: operationalizations, manifestations and etiologies. Hum Mol Genet 29:R10–R18. https://doi.org/10.1093/HMG/DDAA115

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 3:619–627. https://doi.org/10.1016/S2215-0366(16)30065-7

Article  PubMed  Google Scholar 

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt D (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384:1402–1411. https://doi.org/10.1056/NEJMoa2032994

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 16:420–429. https://doi.org/10.1016/S0140-6736(17)32802-7

Article  Google Scholar 

Cristea IA, Fried EI, Kaiser T, Hengartner MP, Turner EH, Naudet F (2024) Maintaining rational expectations about psychedelic interventions. BMJ 385 https://doi.org/10.1136/bmj-2023-078084

Cuijpers P, Cristea IA (2015) What if a placebo effect explained all the activity of depression treatments? World Psychiatry 14:311. https://doi.org/10.1002/WPS.20249

Article  Google Scholar 

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiat 78:481–489. https://doi.org/10.1001/JAMAPSYCHIATRY.2020.3285

Article  Google Scholar 

Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R (2022) Increased global integration in the brain after psilocybin therapy for depression. Nat Med 28:844–851. https://doi.org/10.1038/s41591-022-01744-z

Article  CAS  PubMed  Google Scholar 

Derogatis LR (1977) SCL-90: Administration, scoring & procedures manual for the R(evised) version and other instruments of the psychopathology rating scale series. Johns Hopkins University School of Medicine

Google Scholar 

dos Santos RG, Hallak JEC, Baker G, Dursun S (2021) Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. J Psychopharmacol 35:453–458. https://doi.org/10.1177/0269881120986422

Article  CAS  PubMed  Google Scholar 

Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463. https://doi.org/10.1111/J.0006-341X.2000.00455.X

Article  CAS  PubMed  Google Scholar 

Eisner B, Cohen S (1958) Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 127:528–539

Article  CAS  PubMed  Google Scholar 

Fadiman J, Korb S (2019) Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoactive Drugs 51:118–122. https://doi.org/10.1080/02791072.2019.1593561

Article  PubMed  Google Scholar 

Feijo De Mello M, De Jesus Mari J, Bacaltchuk J, Verdeli H, Neugebauer R (2005) A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 255:75–82. https://doi.org/10.1007/S00406-004-0542-X/METRICS

Article  Google Scholar 

Ferguson CJ (2009) An effect size primer: A guide for clinicians and researchers. Prof Psychol Res Pract 40:532–538. https://doi.org/10.1037/a0015808

Article  Google Scholar 

Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT (2021) Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Exp Clin Psychopharmacol 29:539–554. https://doi.org/10.1037/PHA0000490

Article  CAS  PubMed  Google Scholar 

Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, Timmermann C, Castle D, Rossell SL, Downey LA, Pagni BA, Galvão-Coelho NL, Nutt D, Sarris J (2023) Default mode network modulation by psychedelics: A systematic review. Int J Neuropsychopharmacol 26:155–188. https://doi.org/10.1093/IJNP/PYAC074

Article  CAS  PubMed  Google Scholar 

Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR (2020) The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res 284:112749. https://doi.org/10.1016/J.PSYCHRES.2020.112749

Article  CAS  PubMed  Google Scholar 

Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, … Malievskaia E (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England J Med 387:1637–1648 https://doi.org/10.1056/NEJMOA2206443/SUPPL_FILE/NEJMOA2206443_DATA- SHARING.PDF

Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, … Malievskaia E (2023) Single- dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord 327:120–127. https://doi.org/10.1016/J.JAD.2023.01.108

Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, … Malievskaia E (2025) The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. J Affect Disord 372:523–532 https://doi.org/10.1016/J.JAD.2024.12.061

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstad AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78. https://doi.org/10.1001/ARCHGENPSYCHIATRY.2010.116

Article  CAS  PubMed  Google Scholar 

Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 36:151–158. https://doi.org/10.1177/02698811211073759/ASSET/IMAGES/LARGE/10.1177_02698811211073759-FIG2.JPEG

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haikazian S, Chen-Li DCJ, Johnson DE, Fancy F, Levinta A, Husain MI, Mansur RB, McIntyre RS, Rosenblat JD (2023) Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Res 329:115531. https://doi.org/10.1016/J.PSYCHRES.2023.115531

Article  CAS  PubMed  Google Scholar 

Hall W (2022) Why was early therapeutic research on psychedelic drugs abandoned? Psychol Med 52:26–31. https://doi.org/10.1017/S0033291721004207

Article  PubMed  Google Scholar 

Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S (2024) Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacol Ther 258:108641.